New shot aims to keep TB at bay after treatment
NCT ID NCT03512249
Summary
This study tested whether a new vaccine called H56:IC31 could prevent tuberculosis (TB) from returning in people who had just been successfully treated for it. Over 800 HIV-negative adults in South Africa and Tanzania received either the vaccine or a placebo shot near the end of their standard TB treatment. The main goal was to see if the vaccine reduced the rate of TB disease coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS, PULMONARY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NIMR Mbeya Medical Research Centre
Mbeya, Tanzania
-
South African Tuberculosis Vaccine Initiative , Project Office, Brewelskloof Hospital , Harlem Street, Worcester
Cape Town, Western Cape, 6850, South Africa
-
Task Clinical Research Centre
Bellville, Cape Town, 7530, South Africa
-
The Aurum Institute
Klerksdorp, North West, 2570, South Africa
-
The Aurum Institute: Tembisa Clinical Research Centre
Tembisa, Gauteng, 1632, South Africa
-
University of Cape Town Lung Institute
Mowbray, Cape Town, South Africa
Conditions
Explore the condition pages connected to this study.